{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:25:20Z","timestamp":1769099120467,"version":"3.49.0"},"reference-count":54,"publisher":"Mattioli1885","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,7]]},"abstract":"<jats:p>Background: Malignant pleural mesothelioma (MPM) is a rare highly aggressive tumor strongly associated with asbestos exposure and characterized by poor prognosis. Currently, diagnosis is based on invasive techniques, thus there is a need of identifying non-invasive biomarkers for early detection of the disease among asbestos-exposed subjects. In the present study, we measured the plasmatic concentrations of Mesothelin, Fibulin-3, and HMGB1 protein biomarkers, and of hsa-miR-30e-3p and hsa-miR-103a-3p Extracellular-Vesicles- embedded micro RNAs (EV-miRNAs). We tested the ability of these biomarkers to discriminate between MPM and PAE subjects alone and in combination. Methods: the study was conducted on a population of 26 patients with MPM and 54 healthy subjects with previous asbestos exposure (PAE). Mesothelin, Fibulin-3, and HMGB1 protein biomarkers were measured by the enzyme-linked immunosorbent assay (ELISA) technique; the levels of hsa-miR-30e-3p and hsa-miR-103a-3p EV-miRNAs was assessed by quantitative real-time PCR (qPCR). Results: the most discriminating single biomarker resulted to be Fibulin-3 (AUC 0.94 CI 95% 0.88-1.0; Sensitivity 88%; Specificity 87%). After investigating the different possible combinations, the best performance was obtained by the three protein biomarkers Mesothelin, Fibulin-3, and HMGB1 (AUC 0.99 CI 95% 0.97-1.0; Sensitivity 96%; Specificity 93%). Conclusions: the results obtained contribute to identifying new potential non-invasive biomarkers for the early diagnosis of MPM in high-risk asbestos-exposed subjects. Further studies are needed to validate the evidence obtained, in order to assess the reliability of the proposed biomarker panel.<\/jats:p>","DOI":"10.23749\/mdl.v113i6.13522","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T12:58:01Z","timestamp":1741179481000},"page":"e2022052","source":"Crossref","is-referenced-by-count":1,"title":["Identification of a new potential plasmatic biomarker panel for the diagnosis of malignant pleural mesothelioma"],"prefix":"10.23749","volume":"113","author":[{"given":"Luca","family":"Ferrari","sequence":"first","affiliation":[{"name":"EPIGET Lab, Dipartimento di Scienze Cliniche e di Comunit\u00e0, Universit\u00e0 degli Studi di Milano"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Iodice","sequence":"additional","affiliation":[{"name":"EPIGET Lab, Department of Clinical Sciences and Community Health, Universit\u00e0 degli Studi di Milano"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cantone","sequence":"additional","affiliation":[{"name":"EPIGET Lab, Department of Clinical Sciences and Community Health, Universit\u00e0 degli Studi di Milano"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Dallari","sequence":"additional","affiliation":[{"name":"Occupational Health Unit, Fondazione IRCCS Ca\u2019 Granda - Ospedale Maggiore Policlinico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Dioni","sequence":"additional","affiliation":[{"name":"EPIGET Lab, Department of Clinical Sciences and Community Health, Universit\u00e0 degli Studi di Milano"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Bordini","sequence":"additional","affiliation":[{"name":"Occupational Health Unit, Fondazione IRCCS Ca\u2019 Granda - Ospedale Maggiore Policlinico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Palleschi","sequence":"additional","affiliation":[{"name":"Thoracic Surgery and Lung Transplantation Unit, Fondazione IRCCS Ca\u2019 Granda - Ospedale Maggiore Policlinico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Mensi","sequence":"additional","affiliation":[{"name":"Occupational Health Unit, Fondazione IRCCS Ca\u2019 Granda - Ospedale Maggiore Policlinico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Cecilia","family":"Pesatori","sequence":"additional","affiliation":[{"name":"EPIGET Lab, Department of Clinical Sciences and Community Health, Universit\u00e0 degli Studi di Milano"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27750","reference":[{"key":"10.23749\/mdl.v113i6.13522_ref1","doi-asserted-by":"crossref","unstructured":"Scherpereel A, Scherpereel A, Opitz I, et al. ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953. Doi:10.1183\/13993003.00953-2019","DOI":"10.1183\/13993003.00953-2019"},{"key":"10.23749\/mdl.v113i6.13522_ref2","doi-asserted-by":"crossref","unstructured":"Fazzo L, Binazzi A, Ferrante D, et al. Burden of Mortality from Asbestos-Related Diseases in Italy. Int J Environ Res Public Health. 2021;18(19):10012. Doi:10.3390\/IJERPH181910012","DOI":"10.3390\/ijerph181910012"},{"key":"10.23749\/mdl.v113i6.13522_ref3","unstructured":"International Agency for Research on Cancer (IARC). Mesothelioma. Mesothelioma Globocan 2020. Published 2022. Accessed April 14, 2022. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/18-Mesothelioma-fact-sheet.pdf"},{"key":"10.23749\/mdl.v113i6.13522_ref4","doi-asserted-by":"crossref","unstructured":"Binazzi A, Marzio D Di, Verardo M, et al. Asbestos Exposure and Malignant Mesothelioma in Construction Workers-Epidemiological Remarks by the Italian National Mesothelioma Registry (ReNaM). Int J Environ Res Public Heal. 2022;19:235. Doi:10.3390\/ijerph19010235","DOI":"10.3390\/ijerph19010235"},{"key":"10.23749\/mdl.v113i6.13522_ref5","doi-asserted-by":"crossref","unstructured":"Schumann SO, Kocher G, Minervini F. Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature. J Thorac Dis. 2021;13(4):2510-2523. Doi:10.21037\/JTD-20-2761","DOI":"10.21037\/jtd-20-2761"},{"key":"10.23749\/mdl.v113i6.13522_ref6","doi-asserted-by":"crossref","unstructured":"Bianco A, Valente T, de Rimini ML, Sica G, Fiorelli A. Clinical diagnosis of malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S253-S261. Doi:10.21037\/JTD.2017.10.09","DOI":"10.21037\/jtd.2017.10.09"},{"key":"10.23749\/mdl.v113i6.13522_ref7","doi-asserted-by":"crossref","unstructured":"Wu YB, Xu LL, Wang XJ, et al. Diagnostic value of medical thoracoscopy in malignant pleural effusion. BMC Pulm Med. 2017;17(1):109. Doi:10.1186\/S12890-017-0451-1","DOI":"10.1186\/s12890-017-0451-1"},{"key":"10.23749\/mdl.v113i6.13522_ref8","doi-asserted-by":"crossref","unstructured":"Cinausero M, Rihawi K, Cortiula F, Follador A, Fasola G, Ardizzoni A. Emerging therapies in malignant pleural mesothelioma. Crit Rev Oncol Hematol. 2019;144:102815. Doi:10.1016\/J.CRITREVONC.2019.102815","DOI":"10.1016\/j.critrevonc.2019.102815"},{"key":"10.23749\/mdl.v113i6.13522_ref9","doi-asserted-by":"crossref","unstructured":"Davis A, Ke H, Kao S, Pavlakis N. An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma. Lung Cancer (Auckland, NZ). 2022;13:1-12. Doi:10.2147\/LCTT.S288535","DOI":"10.2147\/LCTT.S288535"},{"key":"10.23749\/mdl.v113i6.13522_ref10","doi-asserted-by":"crossref","unstructured":"Tsao AS, Pass HI, Rimner A, Mansfield AS. New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. J Clin Oncol. 2022;40(6):681-692. Doi:10.1200\/JCO.21.01567","DOI":"10.1200\/JCO.21.01567"},{"key":"10.23749\/mdl.v113i6.13522_ref11","doi-asserted-by":"crossref","unstructured":"Cavallari I, Urso L, Sharova E, Pasello G, Ciminale V. Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives. Front Oncol. 2019;9(AUG):740. Doi:10.3389\/FONC.2019.00740","DOI":"10.3389\/fonc.2019.00740"},{"key":"10.23749\/mdl.v113i6.13522_ref12","doi-asserted-by":"crossref","unstructured":"Ferrari L, Carugno M, Mensi C, Pesatori AC. Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation. Front Oncol. 2020;10:445. Doi:10.3389\/FONC.2020.00445","DOI":"10.3389\/fonc.2020.00445"},{"key":"10.23749\/mdl.v113i6.13522_ref13","doi-asserted-by":"crossref","unstructured":"Poulet G, Massias J, Taly V. Liquid Biopsy: General Concepts. Acta Cytol. 2019;63(6):449-455. Doi:10.1159\/000499337","DOI":"10.1159\/000499337"},{"key":"10.23749\/mdl.v113i6.13522_ref14","doi-asserted-by":"crossref","unstructured":"Armato SG, Nowak AK, Francis RJ, et al. Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group. Lung Cancer. 2022;164:76-83. Doi:10.1016\/J.LUNGCAN.2021.12.008","DOI":"10.1016\/j.lungcan.2021.12.008"},{"key":"10.23749\/mdl.v113i6.13522_ref15","doi-asserted-by":"crossref","unstructured":"Schillebeeckx E, van Meerbeeck JP, Lamote K. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis. Eur Respir Rev. 2021;30(162):210057. Doi:10.1183\/16000617.0057-2021","DOI":"10.1183\/16000617.0057-2021"},{"key":"10.23749\/mdl.v113i6.13522_ref16","doi-asserted-by":"crossref","unstructured":"Tomasetti M, Amati M, Neuzil J, Santarelli L. Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy. Lung Cancer. 2017;107:65-72. Doi:10.1016\/J.LUNGCAN.2016.05.023","DOI":"10.1016\/j.lungcan.2016.05.023"},{"key":"10.23749\/mdl.v113i6.13522_ref17","doi-asserted-by":"crossref","unstructured":"van Niel G, D\u2019Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213-228. Doi:10.1038\/nrm.2017.125","DOI":"10.1038\/nrm.2017.125"},{"key":"10.23749\/mdl.v113i6.13522_ref18","doi-asserted-by":"crossref","unstructured":"Shah R, Patel T, Freedman JE. Circulating extracellular vesicles in human disease. N Engl J Med. Published online 2018. Doi:10.1056\/NEJMra1704286","DOI":"10.1056\/NEJMra1704286"},{"key":"10.23749\/mdl.v113i6.13522_ref19","doi-asserted-by":"crossref","unstructured":"Lucchetti D, Ricciardi Tenore C, Colella F, Sgambato A. Extracellular Vesicles and Cancer: A Focus on Metabolism, Cytokines, and Immunity. Cancers (Basel). 2020;12(1):171. Doi:10.3390\/cancers12010171","DOI":"10.3390\/cancers12010171"},{"key":"10.23749\/mdl.v113i6.13522_ref20","doi-asserted-by":"crossref","unstructured":"Cavalleri T, Angelici L, Favero C, et al. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease. PLoS One. 2017;12(5):e0176680. Doi:10.1371\/JOURNAL.PONE.0176680","DOI":"10.1371\/journal.pone.0176680"},{"key":"10.23749\/mdl.v113i6.13522_ref21","doi-asserted-by":"crossref","unstructured":"Nowak AK, Chansky K, Rice DC, et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016;11(12):2089-2099. Doi:10.1016\/J.JTHO.2016.08.147","DOI":"10.1016\/j.jtho.2016.08.147"},{"key":"10.23749\/mdl.v113i6.13522_ref22","doi-asserted-by":"crossref","unstructured":"Rice D, Chansky K, Nowak A, et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016;11(12):2100-2111. Doi:10.1016\/J.JTHO.2016.09.121","DOI":"10.1016\/j.jtho.2016.09.121"},{"key":"10.23749\/mdl.v113i6.13522_ref23","doi-asserted-by":"crossref","unstructured":"Pass H, Giroux D, Kennedy C, et al. The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. J Thorac Oncol. 2016;11(12):2082-2088. Doi:10.1016\/J.JTHO.2016.09.123","DOI":"10.1016\/j.jtho.2016.09.123"},{"key":"10.23749\/mdl.v113i6.13522_ref24","doi-asserted-by":"crossref","unstructured":"Marinaccio A, Binazzi A, Marzio D Di, et al. Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register. Int J cancer. 2012;130(9):2146-2154. Doi:10.1002\/IJC.26229","DOI":"10.1002\/ijc.26229"},{"key":"10.23749\/mdl.v113i6.13522_ref25","doi-asserted-by":"crossref","unstructured":"Weber DG, Casjens S, Johnen G, et al. Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis. Altomare DA, ed. PLoS One. 2014;9(12):e114483. Doi:10.1371\/journal.pone.0114483","DOI":"10.1371\/journal.pone.0114483"},{"key":"10.23749\/mdl.v113i6.13522_ref26","doi-asserted-by":"crossref","unstructured":"Tsim S, Alexander L, Kelly C, et al. Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases. J Thorac Oncol. 2021;16(10):1705-1717. Doi:10.1016\/j.jtho.2021.05.018","DOI":"10.1016\/j.jtho.2021.05.018"},{"key":"10.23749\/mdl.v113i6.13522_ref27","doi-asserted-by":"crossref","unstructured":"Handke N, Rupp A, Trimpop N, von Pawel J, Holdenrieder S. Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients. Diagnostics. 2021;11(2):356. Doi:10.3390\/diagnostics11020356","DOI":"10.3390\/diagnostics11020356"},{"key":"10.23749\/mdl.v113i6.13522_ref28","doi-asserted-by":"crossref","unstructured":"Scherpereel A, Scherpereel A, Opitz I, et al. ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953. Doi:10.1183\/13993003.00953-2019","DOI":"10.1183\/13993003.00953-2019"},{"key":"10.23749\/mdl.v113i6.13522_ref29","doi-asserted-by":"crossref","unstructured":"Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem. 2013;13(2):276-280. Doi:10.2174\/1871520611313020014","DOI":"10.2174\/1871520611313020014"},{"key":"10.23749\/mdl.v113i6.13522_ref30","doi-asserted-by":"crossref","unstructured":"Chen Z, Gaudino G, Pass HI, Carbone M, Yang H. Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. Transl lung cancer Res. 2017;6(3):259-269. Doi:10.21037\/TLCR.2017.05.06","DOI":"10.21037\/tlcr.2017.05.06"},{"key":"10.23749\/mdl.v113i6.13522_ref31","doi-asserted-by":"crossref","unstructured":"Cristaudo A, Bonotti A, Guglielmi G, Fallahi P, Foddis R. Serum mesothelin and other biomarkers: what have we learned in the last decade? J Thorac Dis. 2018;10(Suppl 2):S353-S359. Doi:10.21037\/JTD.2017.10.132","DOI":"10.21037\/jtd.2017.10.132"},{"key":"10.23749\/mdl.v113i6.13522_ref32","doi-asserted-by":"crossref","unstructured":"Pass HI, Alimi M, Carbone M, Yang H, Goparaju CM. Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2524-2540. Doi:10.1158\/1055-9965.EPI-20-0083","DOI":"10.1158\/1055-9965.EPI-20-0083"},{"key":"10.23749\/mdl.v113i6.13522_ref33","doi-asserted-by":"crossref","unstructured":"Hwang CF, Chien CY, Huang SC, et al. Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol. 2010;222(4):367-379. Doi:10.1002\/PATH.2776","DOI":"10.1002\/path.2776"},{"key":"10.23749\/mdl.v113i6.13522_ref34","doi-asserted-by":"crossref","unstructured":"Pass HI, Levin SM, Harbut MR, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012;367(15):1417-1427. Doi:10.1056\/NEJMOA1115050","DOI":"10.1056\/NEJMoa1115050"},{"key":"10.23749\/mdl.v113i6.13522_ref35","doi-asserted-by":"crossref","unstructured":"Creaney J, Dick IM, Robinson BW. Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma. Curr Opin Pulm Med. 2015;21(4):352-356. Doi:10.1097\/MCP.0000000000000167","DOI":"10.1097\/MCP.0000000000000167"},{"key":"10.23749\/mdl.v113i6.13522_ref36","doi-asserted-by":"crossref","unstructured":"Pei D, Li Y, Liu X, et al. Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis. Oncotarget. 2017;8(8):13030-13038. Doi:10.18632\/ONCOTARGET.14712","DOI":"10.18632\/oncotarget.14712"},{"key":"10.23749\/mdl.v113i6.13522_ref37","doi-asserted-by":"crossref","unstructured":"Kaya H, Demir M, Taylan M, et al. Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma. Asian Pac J Cancer Prev. 2015;16(4):1403-1407. Doi:10.7314\/APJCP.2015.16.4.1403","DOI":"10.7314\/APJCP.2015.16.4.1403"},{"key":"10.23749\/mdl.v113i6.13522_ref38","doi-asserted-by":"crossref","unstructured":"Hassan MH, Abuhamdah S, Abdel-Bary M, et al. Circulating and local nuclear expression of survivin and fibulin-3 genes in discriminating benign from malignant respiratory diseases: correlation analysis. Biosci Rep. 2021;41(1): BSR20203097. Doi:10.1042\/BSR20203097","DOI":"10.1042\/BSR20203097"},{"key":"10.23749\/mdl.v113i6.13522_ref39","doi-asserted-by":"crossref","unstructured":"Jiang Z, Ying S, Shen W, et al. Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population. Dis Markers. 2017;2017:1725354 Doi:10.1155\/2017\/1725354","DOI":"10.1155\/2017\/1725354"},{"key":"10.23749\/mdl.v113i6.13522_ref40","doi-asserted-by":"crossref","unstructured":"Creaney J, Dick IM, Meniawy TM, et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax. 2014;69(10):895-902. Doi:10.1136\/thoraxjnl-2014-205205","DOI":"10.1136\/thoraxjnl-2014-205205"},{"key":"10.23749\/mdl.v113i6.13522_ref41","doi-asserted-by":"crossref","unstructured":"Kirschner MB, Pulford E, Hoda MA, et al. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer. 2015;113(6):963-969. Doi:10.1038\/BJC.2015.286","DOI":"10.1038\/bjc.2015.286"},{"key":"10.23749\/mdl.v113i6.13522_ref42","doi-asserted-by":"crossref","unstructured":"Napolitano A, Antoine DJ, Pellegrini L, et al. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. Clin Cancer Res. 2016;22(12):3087-3096. Doi:10.1158\/1078-0432.CCR-15-1130","DOI":"10.1158\/1078-0432.CCR-15-1130"},{"key":"10.23749\/mdl.v113i6.13522_ref43","doi-asserted-by":"crossref","unstructured":"Yang H, Rivera Z, Jube S, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A. 2010;107(28):12611-16. Doi:10.1073\/PNAS.1006542107\/-\/DCSUPPLEMENTAL\/PNAS.201006542SI.PDF","DOI":"10.1073\/pnas.1006542107"},{"key":"10.23749\/mdl.v113i6.13522_ref44","doi-asserted-by":"crossref","unstructured":"Wang S, Zhang Y. HMGB1 in inflammation and cancer. J Hematol Oncol. 2020;13(1):1-4. Doi:10.1186\/S13045-020-00950-X\/FIGURES\/1","DOI":"10.1186\/s13045-020-00950-x"},{"key":"10.23749\/mdl.v113i6.13522_ref45","doi-asserted-by":"crossref","unstructured":"Jube S, Rivera ZS, Bianchi ME, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012;72(13):3290-3301. Doi:10.1158\/0008-5472.CAN-11-3481","DOI":"10.1158\/0008-5472.CAN-11-3481"},{"key":"10.23749\/mdl.v113i6.13522_ref46","doi-asserted-by":"crossref","unstructured":"Mezzapelle R, De Marchis F, Passera C, et al. CXCR4 engagement triggers CD47 internalization and antitumor immunization in a mouse model of mesothelioma. EMBO Mol Med. 2021;13(6):e12344. Doi:10.15252\/EMMM.202012344","DOI":"10.15252\/emmm.202012344"},{"key":"10.23749\/mdl.v113i6.13522_ref47","doi-asserted-by":"crossref","unstructured":"Ying S, Jiang Z, He X, et al. Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases. Dis Markers. 2017;2017:5756102. Doi:10.1155\/2017\/5756102","DOI":"10.1155\/2017\/5756102"},{"key":"10.23749\/mdl.v113i6.13522_ref48","doi-asserted-by":"crossref","unstructured":"Tabata C, Shibata E, Tabata R, et al. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer. 2013;13(1):1-6. Doi:10.1186\/1471-2407-13-205\/FIGURES\/3","DOI":"10.1186\/1471-2407-13-205"},{"key":"10.23749\/mdl.v113i6.13522_ref49","doi-asserted-by":"crossref","unstructured":"Napolitano A, Antoine DJ, Pellegrini L, et al. Expression of Concern: HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. Clin Cancer Res. 2020;26(6):1529. Doi:10.1158\/1078-0432.CCR-20-0338","DOI":"10.1158\/1078-0432.CCR-20-0338"},{"key":"10.23749\/mdl.v113i6.13522_ref50","doi-asserted-by":"crossref","unstructured":"Han YQ, Xu SC, Zheng WQ, Hu Z De. Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini-review. Thorac cancer. 2021;12(1):8-12. Doi:10.1111\/1759-7714.13746","DOI":"10.1111\/1759-7714.13746"},{"key":"10.23749\/mdl.v113i6.13522_ref51","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Rivera V, Negrete-Garc\u00eda MC, \u00c1vila-Moreno F, Ortiz-Quintero B. Secreted and tissue miRNAs as diagnosis biomarkers of malignant pleural mesothelioma. Int J Mol Sci. 2018;19(2):595. Doi:10.3390\/ijms19020595","DOI":"10.3390\/ijms19020595"},{"key":"10.23749\/mdl.v113i6.13522_ref52","doi-asserted-by":"crossref","unstructured":"Filip\u00f3w S, \u0141aczma\u0144ski \u0141. Blood Circulating miRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response. Front Genet. 2019;10(FEB):169. Doi:10.3389\/FGENE.2019.00169","DOI":"10.3389\/fgene.2019.00169"},{"key":"10.23749\/mdl.v113i6.13522_ref53","doi-asserted-by":"crossref","unstructured":"Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2021;21(1):22-36. Doi:10.1038\/S41568-020-00306-0","DOI":"10.1038\/s41568-020-00306-0"},{"key":"10.23749\/mdl.v113i6.13522_ref54","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Ram\u00edrez C, Casjens S, Ju\u00e1rez-P\u00e9rez CA, et al. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma. Lung. 2019;197(5):641-649. Doi:10.1007\/S00408-019-00244-1","DOI":"10.1007\/s00408-019-00244-1"}],"container-title":["La Medicina del Lavoro","La Medicina del Lavoro | Work, Environment and Health"],"original-title":[],"link":[{"URL":"https:\/\/mattioli1885journals.com\/index.php\/lamedicinadellavoro\/article\/download\/13522\/11092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mattioli1885journals.com\/index.php\/lamedicinadellavoro\/article\/download\/13522\/11092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:20:58Z","timestamp":1741792858000},"score":1,"resource":{"primary":{"URL":"https:\/\/mattioli1885journals.com\/index.php\/lamedicinadellavoro\/article\/view\/13522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":54,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.23749\/mdl.v113i6.13522","relation":{"has-manifestation":[{"id-type":"other","id":"4-846-13522-g11092","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"4-846","asserted-by":"subject"}]},"ISSN":["2532-1080","0025-7818"],"issn-type":[{"value":"2532-1080","type":"electronic"},{"value":"0025-7818","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,7]]},"article-number":"3"}}